Therapeutic drug monitoring does not improve remission for patients starting infliximab

ATLANTA — New research presented at ACR Convergence, the American College Rheumatology’s annual meeting, showed that patients with rheumatic diseases whose infliximab treatment was individually assessed and adjusted with a new strategy called therapeutic drug monitoring did not achieve remission at higher rates compared to those who received standard care. (ABSTRACT #2029) Tumor necrosis factor […]